Novavax Inc (NVAX)
Industry Biotechnology
This stock can be held in an Investment ISA and an Investment Account
Sell
$12.67
Buy
$12.69
$1.74 (+15.80%)
Prices updated at 10 Oct 2026, 00:59 EDT
| Prices minimum 15 mins delay
Prices in USD
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish sub ...
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Income statement
Year | 2024 | 2025 |
|---|---|---|
| 682m | 1,123m | |
| 479m | 1,050m | |
| -249m | 551m | |
| -36.49 | 49.01 | |
| -187m | 440m | |
| -108m | 492m | |
| Sales, General and administrative | 337m | 157m |
| Interest expenses | 20m | 23m |
| Provision for income taxes | 11m | 2m |
| Operating expenses | 728m | 500m |
| Income before taxes | -177m | 442m |
| Net income available to common shareholders | -187m | 440m |
| -1.23 | 2.72 | |
| Net interest income | -20m | -23m |
| Advertising and promotion | - | - |
| Net investment income, net | - | - |
| Realised capital gains (losses), net | - | - |
| Total benefits, claims and expenses | - | - |
| Earnings per share (diluted) | -1.23 | 2.58 |
| Free cash flow per share | -0.7851 | -2.3145 |
| Book value/share | -3.2816 | -0.9637 |
| Debt equity ratio | - | - |
Balance sheet
Year | 2024 | 2025 |
|---|---|---|
| Current assets | 1,129m | 978m |
| Current liabilities | 1,154m | 460m |
| Total capital | -454m | 116m |
| Total debt | 230m | 249m |
| Total equity | -624m | -128m |
| Total non current liabilities | - | - |
| Loans | 170m | 244m |
| Total assets | 1,560m | 1,177m |
| Total liabilities | - | - |
| Cash and cash equivalents | 530m | 241m |
| Common stock | 160m | 163m |
Cash flow
Year | 2024 | 2025 |
|---|---|---|
| Cash at beginning of period | 584m | 545m |
| Cash dividends paid | - | - |
| -102m | -251m | |
| Investments (gains) losses | -204m | -78m |
| 545m | 256m | |
| Net income | - | - |
| -87m | -245m | |
| -15m | -6m |
The figures shown in the tables are quoted in the currency of the stock selected.
Please note that past performance is not a reliable indicator of future returns. Please use the interactive graph for benchmark comparison.
